First small molecule found to block coronavirus M-N protein interaction
- An aminopyrimidine series built from a pyrimidine lead was profiled for anti-HCoV-OC43 activity in cells.
- Top compound 13h paired strong potency with a wide selectivity window and a good safety profile.
- It appears to bind residue V201 of the membrane protein M at the M-N interface, disrupting the association needed for virion assembly.
- First small molecule aimed at this interface, with a mechanism unlike existing coronavirus drugs.
💡 Points Based on the abstract
Most coronavirus antivirals hit the protease or polymerase, where resistance routes are well mapped; a virion-assembly interface is a genuinely different bet. The next step is a V201 mutant that loses both binding and antiviral effect, plus SPR or a thermal shift on M, and a check that 13h doesn't simply act on a host kinase.